In a report issued on October 28, Difei Yang from Mizuho Securities reiterated a Buy rating on Aerie Pharma (AERI – Research Report), with a price target of $27.00. The company’s shares closed last Wednesday at $10.89, close to its 52-week low of $9.01.
According to TipRanks.com, Yang is ranked 0 out of 5 stars with an average return of -10.0% and a 32.2% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals, Sarepta Therapeutics, and Revance Therapeutics.
Currently, the analyst consensus on Aerie Pharma is a Strong Buy with an average price target of $26.91, a 144.2% upside from current levels. In a report issued on October 20, Oppenheimer also maintained a Buy rating on the stock with a $24.00 price target.
Based on Aerie Pharma’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $18.03 million and GAAP net loss of $48.19 million. In comparison, last year the company earned revenue of $15.84 million and had a GAAP net loss of $47.16 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.